Evaluating Strategies for the Treatment of Cerebral Cavernous Malformations
Authors:
- 1 October 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 41 (10_suppl_1) , S92-4
Abstract
Cerebral cavernous malformations are common vascular lesions of the central nervous system that predispose to seizures, focal neurological deficits, and potentially fatal hemorrhagic stroke. Human genetic studies have identified 3 genes associated with the disease, and biochemical studies of these proteins have identified interaction partners and possible signaling pathways. A recurring theme dominating the recent scientific literature is the causal link between mutations in the 3 cerebral cavernous malformation genes and hyperactivation of the small GTP exchange protein, RhoA, and the efficacy of reducing this hyperactivation using inexpensive and well-studied medicines, statins. Familial cerebral cavernous malformation offers a unique opportunity to use a personalized genomic medicine approach to identify a subset of patients prone to intracerebal hemorrhage that may benefit from a pharmacological therapy, where presently only neurosurgical options are available.Keywords
This publication has 32 references indexed in Scilit:
- Crystal Structure of CCM3, a Cerebral Cavernous Malformation Protein Critical for Vascular IntegrityJournal of Biological Chemistry, 2010
- Rho Kinase Inhibition Rescues the Endothelial Cell Cerebral Cavernous Malformation PhenotypeJournal of Biological Chemistry, 2010
- Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrityJournal of Experimental Medicine, 2010
- Endogenous endothelial cell signaling systems maintain vascular stabilityAngiogenesis, 2009
- Regulation of cardiovascular development and integrity by the heart of glass–cerebral cavernous malformation protein pathwayNature Medicine, 2009
- The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPasesNature Medicine, 2009
- Biallelic somatic and germline mutations in cerebral cavernous malformations (CCMs): evidence for a two-hit mechanism of CCM pathogenesisHuman Molecular Genetics, 2008
- Angiotensin II Blockade and Aortic-Root Dilation in Marfan's SyndromeNew England Journal of Medicine, 2008
- KRIT-1/CCM1 is a Rap1 effector that regulates endothelial cell–cell junctionsJournal of Cell Biology, 2007
- Deletions in CCM2 Are a Common Cause of Cerebral Cavernous MalformationsThe American Journal of Human Genetics, 2007